Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06928389 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Ivonescimab in Combination With Docetaxel in Advanced Non-Small Cell Lung Cancer

Name: Ivonescimab in Combination With Docetaxel in Advanced Non-Small Cell Lung Cancer — clinical trial record (NCT06928389)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: NSCLC

StatusRecruiting

PhasePhase 3

SponsorAkeso

Started2025-07-08

View on ClinicalTrials.gov ↗

Amendment history

2026-04-07

Not Yet Recruiting→Recruiting Study Status, Contacts/Locations v2

Trial statusNot Yet Recruiting→Recruiting

Start dateestimated 2025-06→confirmed 2025-07-08

Study sites0→1

2025-04-29

Study Status v1

Re-verified, no change to tracked fields

2025-04-08

Original filing

Akeso

96 trials monitored

See 1 trial at risk

Lung Cancer

4,033 trials monitored

See 210 trials at risk

Non-Small Cell Lung Cancer (NSCLC)

2,914 trials monitored

See 156 trials at risk

This is a Phase 3 Randomized, double-blind, Multicenter Study of Ivonescimab Combined with Docetaxel Versus Placebo Combined with Docetaxel in Patients with Locally advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) that has progressed on or after PD-(L)1 inhibitor-based therapy. The purpose of this study is to evaluate the efficacy and safety of ivonescimab versus placebo, combined with docetaxel in patients with advanced NSCLC.

Trial Details

NCT Number	NCT06928389
Lead Sponsor	Akeso
Conditions	Non-Small Cell Lung Cancer
Enrollment	536 participants
Start Date	2025-07-08
Primary Completion	2027-05 (estimated)
Study Completion	2030-06 (estimated)
Updated on ClinicalTrials.gov	2026-04-09